<DOC>
	<DOCNO>NCT00565448</DOCNO>
	<brief_summary>The primary objective estimate Complete Response rate docetaxel combination cisplatin-5-fluorouracil ( TCF ) compare cisplatin-5-fluorouracil ( CF ) Induction treatment Nasopharyngeal Carcinoma ( NPC ) . The secondary objective determine : - safety TCF comparison CF induction treatment NPC , - pharmacokinetics docetaxel added CF , - Overall Response rate TCF CF completion induction consolidation ( chemo-radiotherapy ) treatment NPC , compare overall survival TCF CF .</brief_summary>
	<brief_title>Docetaxel Combination With Cisplatin-5-fluorouracil Induction Treatment Nasopharyngeal Carcinoma Children Adolescents</brief_title>
	<detailed_description>Planned treatment duration : - induction period : 9 week induction treatment - consolidation period : 9 week chemoradiation treatment . The consolidation treatment participant : radiation therapy 7-8 week 3 cycle cisplatin 100 mg/m² every 3 week .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histological diagnosis nasopharyngeal carcinoma World Health Organization ( WHO ) type II III Children adolescents newly diagnose Stage IIBIV NPC measurable disease , &gt; 1 month ≤21 year age time diagnosis . In France , participant must ≥1 year ≤21 year age time diagnosis Participants short life expectancy Prior chemotherapy radiotherapy nasopharynx neck treatment nasopharyngeal carcinoma Inadequate renal function evidence unacceptable laboratory result The information intend contain consideration relevant participant 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Nasopharyngeal carcinoma</keyword>
</DOC>